 "Granules India buys 12.5% stake in USpharma")
Don't want to miss the best from Business Standard?
The Hyderabad-based pharma firm Granules India Ltd, through its wholly owned subsidiary Granules Pharmaceuticals Inc (GPI), has entered into an agreement to acquire 12.5 percent stake in the US-based USpharma. This investment will enable Granules to participate in product selection and have right of first refusal to market the select products which are under development by USpharma.
USpharma is a development-stage pharmaceutical company specialising in research, development and manufacture of high entry-barrier generic pharmaceuticals, including controlled-release, controlled-substance and patent-challenge products. USpharma in collaboration with manufacturing partners had submitted five ANDAs with Paragraph IV certifications, out of which four ANDAs have already been out licensed to Granules exclusively.
ALSO READ: Granules India bags exclusive rights for USpharma Windlas' four products
ALSO READ: Granules India bags exclusive rights for USpharma Windlas' four products
USpharma has formulation development and manufacturing facilities in Philadelphia (USA), Mumbai and cGMP analytical laboratory in Kansas City (USA).
“The agreement with USpharma complements our internal product development program and expands our product portfolio by leveraging external product development capabilities. The successful development of limited competition products by USpharma provides further long-term growth for the company. We are impressed with USpharma's product development capabilities with niche pipeline and firmly believe that these products represent a substantial commercial opportunity,” said Krishna Prasad Chigurupati, chairman and managing director, Granules India Ltd.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%